-
Pediatric Dentistry Jul 2021An altered sense of taste (dysgeusia) has been associated with COVID-19 infection in adults but is not sufficiently documented in children. The purpose of this study...
An altered sense of taste (dysgeusia) has been associated with COVID-19 infection in adults but is not sufficiently documented in children. The purpose of this study was to assess the odds ratio for dysgeusia associated with COVID-19 in a pediatric population of a major health center. Deidentified aggregate data, provided by the chief data officer (Informatics for Integrating Biology and the Bedside-I2B2) from June 2015 to October 2020, was used for correlation using the dysgeusia code (ICD 10 R43.2) with and without positivity for COVID-19. COVID-19 patients were measured from January 2020 to October 2020. Among the 552 children who tested positive for COVID-19, nine also tested positive for dysgeusia and were older than nine years of age (odds ratio equals 149.5; 95 percent confidence interval equals 66.9 to 334.3; P<0.001). Based on a strong association between COVID-19 and dysgeusia in children, dental professionals treating children are recommended to include questions about recent changes in appetite and taste as part of their patient screening COVID-19 questionnaire.
Topics: Adult; COVID-19; Child; Dysgeusia; Humans; Olfaction Disorders; Prevalence; SARS-CoV-2
PubMed: 34467844
DOI: No ID Found -
Revista Espanola de Geriatria Y... 2022
Topics: Aged; COVID-19; Dysgeusia; Humans; Patients; SARS-CoV-2
PubMed: 34315615
DOI: 10.1016/j.regg.2021.05.008 -
Internal Medicine (Tokyo, Japan) Mar 2020Dysgeusia is rare in Guillain-Barré syndrome, particularly as the initial symptom. We herein report the case of a 59-year-old woman who presented with only dysgeusia as...
Dysgeusia is rare in Guillain-Barré syndrome, particularly as the initial symptom. We herein report the case of a 59-year-old woman who presented with only dysgeusia as the initial symptom of Guillain-Barré syndrome, followed by gradually worsening muscle weakness and bilateral sensory disturbances in the extremities. Her dysgeusia was so unpleasant that she could not eat anything, so she received nasogastric tube feeding without dysphasia. We speculate that the dysgeusia in our patient was mainly caused by inflammation of the chorda tympani nerves. Guillain-Barré syndrome should be considered a possible cause of acute dysgeusia.
Topics: Dysgeusia; Female; Guillain-Barre Syndrome; Humans; Middle Aged; Muscle Weakness
PubMed: 31813908
DOI: 10.2169/internalmedicine.2417-18 -
Cancer Treatment Reviews Apr 2016Combined-modality treatment of head and neck cancer is becoming more common, driven by the idea that organ(s) preservation should maintain patient appearance and the... (Review)
Review
The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: A systematic review.
BACKGROUND
Combined-modality treatment of head and neck cancer is becoming more common, driven by the idea that organ(s) preservation should maintain patient appearance and the function of organ(s) involved. Even if treatments have improved, they can still be associated with acute and late adverse effects. The aim of this systematic review was to retrieve current data on how swallowing disorders, dysgeusia, oral mucositis, and xerostomia affect nutritional status, oral intake and weight loss in head and neck cancer (HNC) patients.
METHODS
A systematic literature search covered four relevant electronic databases from January 2005 to May 2015. Retrieved papers were categorised and evaluated considering their methodological quality. Two independent reviewers reviewed manuscripts and abstracted data using a standardised form. Quality assessment of the included studies was performed using the Edwards Method Score.
RESULTS
Of the 1459 abstracts reviewed, a total of 25 studies were included. The most studied symptom was dysphagia, even if symptoms were interconnected and affected one other. In most of the selected studies the level of evidence was between 2 and 3, and their quality level was from medium to low.
CONCLUSIONS
There are limited data about dysgeusia, oral mucositis and xerostomia outcomes available for HNC patients. There is a lack of well-designed clinical trials and multicenter-prospective cohort studies, therefore further research is needed to ascertain which aspects of these symptoms should be measured.
Topics: Combined Modality Therapy; Deglutition Disorders; Dysgeusia; Head and Neck Neoplasms; Humans; Nutritional Status; Outcome Assessment, Health Care; Quality of Life; Stomatitis; Weight Loss; Xerostomia
PubMed: 27010487
DOI: 10.1016/j.ctrv.2016.03.006 -
Anticancer Research Nov 2018Dysgeusia is one of the adverse events frequently affecting patients undergoing cancer chemotherapy. Dysgeusia-induced anorexia could decrease patient's quality of life....
BACKGROUND/AIM
Dysgeusia is one of the adverse events frequently affecting patients undergoing cancer chemotherapy. Dysgeusia-induced anorexia could decrease patient's quality of life. The present study was designed to determine whether the zinc-containing compound polaprezinc improves chemotherapy-induced dysgeusia.
PATIENTS AND METHODS
The incidence of grade 2 dysgeusia was assessed in 634 patients receiving cancer chemotherapy in outpatient settings during January 2013 and June 2017. Polaprezinc was administered to patients showing grade 2 dysgeusia and the effect was compared with that in patients subjected to follow-up observation.
RESULTS
Grade 2 dysgeusia appeared in 80 patients (12.6%), in whom pancreatic cancer and treatment with fluoropyrimidines were significant risks for dysgeusia. Polaprezinc, when administered to patients with grade 2 dysgeusia, significantly shortened the duration of dysgeusia compared with that in the follow-up observation group. Subgroup analysis indicated that polaprezinc was less effective in patients with pancreatic cancer, those receiving gemcitabine, or those whose age was 65 year-old and over.
CONCLUSION
Chemotherapy-induced dysgeusia occurred with high frequency in patients with pancreatic cancer or in those receiving fluoropyrimidines. Polaprezinc was highly effective in improving the symptom of dysgeusia, except for patients with pancreatic cancer, those receiving gemcitabine and the elderly.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carnosine; Drug Therapy; Dysgeusia; Female; Humans; Male; Middle Aged; Organometallic Compounds; Outpatients; Pancreatic Neoplasms; Quality of Life; Treatment Outcome; Young Adult; Zinc Compounds
PubMed: 30396959
DOI: 10.21873/anticanres.12995 -
Journal of Biomolecular Structure &... Apr 2023The COVID-19 pandemic is a very contagious respiratory illness with has affected millions of individuals worldwide. In addition to the well-known symptoms of any...
The COVID-19 pandemic is a very contagious respiratory illness with has affected millions of individuals worldwide. In addition to the well-known symptoms of any respiratory virus, COVID-19 can present with anosmia (failure to smell) and dysgeusia (distortion of the sense of taste). It appears to be a genetic link to the biological mechanisms underlying COVID-19-related anosmia and dysgeusia. Significant locus in the vicinity of the UGT2A1 and UGT2A2 genes are currently considered as the main culprit of the symptoms. However, more studies are needed to delineate a clear pathophysiology.Communicated by Ramaswamy H. Sarma.
Topics: Humans; COVID-19; Dysgeusia; Smell; Taste; Anosmia; Pandemics; SARS-CoV-2; Olfaction Disorders; Glucuronosyltransferase
PubMed: 35147485
DOI: 10.1080/07391102.2022.2039773 -
Cancer Nov 2022Dysgeusia is a common but understudied complication in patients undergoing autologous hematopoietic cell transplantation (auto-HCT). We assessed the feasibility of using...
BACKGROUND
Dysgeusia is a common but understudied complication in patients undergoing autologous hematopoietic cell transplantation (auto-HCT). We assessed the feasibility of using chemical gustometry (CG) to measure dysgeusia and explored its associations with symptom burden, nutrition, chemotherapy pharmacokinetics (PK), and the oral microbiome.
METHODS
We conducted a single-center, prospective feasibility study (NCT03276481) of patients with multiple myeloma undergoing auto-HCT. CG was performed longitudinally testing five flavors (sweet, sour, salty, bitter, umami) to calculate a total taste score (maximum score, 30). We measured caloric intake and patient-reported symptoms, assessing their correlation with oral microbiota composition and salivary and blood melphalan PK exposure.
RESULTS
Among all 45 patients, 39 (87%) completed at least four (>60%) and 22 (49%) completed all six CG assessments. Median total CG scores remained stable over time but were lowest at day +7 (27, range 24-30) with recovery by day +100. Symptom burden was highest by day +10 (area under the curve, 2.9; range, 1.0-4.6) corresponding with the lowest median overall caloric intake (1624 kcal; range, 1345-2267). Higher serum/salivary melphalan levels correlated with higher patient-reported dysgeusia and lower caloric intake. Oral microbiota α-diversity was stable early and increased slightly by day +100.
CONCLUSIONS
Assessment of dysgeusia by CG is feasible after auto-HCT. Most dysgeusia, symptom burden, and lowest caloric intake occurred during the blood count nadir. Higher melphalan concentrations correlated with more dysgeusia and poorer caloric intake. Future studies will aim to modulate melphalan exposure by PK-targeted dosing and characterize patient taste preferences to personalize diets for improved nutritional intake.
LAY SUMMARY
Taste changes after cancer treatments are very common. We used chemical gustometry (taste testing) to study taste changes and to better understand why patients with multiple myeloma experience this symptom after autologous hematopoietic cell transplantation. We found that taste testing was feasible, taste changes peaked when blood counts were lowest, and most patients recovered their taste by 100 days after transplantation. Taste changes correlated with lower food intake and with higher levels of chemotherapy in the body. Future work will focus on using personalized chemotherapy doses to reduce taste changes and to match patients' individual taste preferences with their diets.
Topics: Dysgeusia; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prospective Studies; Transplantation, Autologous
PubMed: 36041227
DOI: 10.1002/cncr.34444 -
The Laryngoscope May 2005
Topics: Botulinum Toxins, Type A; Dysgeusia; Facial Nerve; Facial Nerve Diseases; Humans; Incidental Findings; Medical Informatics; Neuromuscular Agents; Public Health
PubMed: 15867635
DOI: 10.1097/00005537-200505000-00002 -
The Journal of Neuropsychiatry and... 2012
Topics: Aged; Antidepressive Agents; Dysgeusia; Humans; Male; Sertraline
PubMed: 22772699
DOI: 10.1176/appi.neuropsych.11040095 -
BMJ Case Reports Nov 2017Common adverse effects of serotonin-norepinephrine reuptake inhibitors are nausea, dry mouth, dizziness and headache. We describe the case of a patient with dysosmia and...
Common adverse effects of serotonin-norepinephrine reuptake inhibitors are nausea, dry mouth, dizziness and headache. We describe the case of a patient with dysosmia and subsequent dysgeusia associated with duloxetine. A 68-year-old Japanese woman with a history of type 1 diabetes mellitus, hypertension, insomnia and reflux esophagitis presented to a local hospital with bilateral leg pain; she was treated with duloxetine. However, after 4 weeks, she sensed rotten egg smell, experienced nausea and vomiting and was admitted to our hospital. We diagnosed dysosmia using the T&T olfactometer threshold test and dysgeusia using filter paper disk method. Taste was assessed using electrogustometry. We suspected that dysosmia and dysgeusia were adverse effects of duloxetine. After stopping duloxetine, her symptoms gradually subsided and the above test results improved, despite continuing the other ongoing medication. To the best of our knowledge, this is the first case report of dysosmia and dysgeusia associated with duloxetine.
Topics: Aged; Duloxetine Hydrochloride; Dysgeusia; Female; Humans; Olfaction Disorders; Serotonin and Noradrenaline Reuptake Inhibitors
PubMed: 29170185
DOI: 10.1136/bcr-2017-222470